Daré Bioscience, Inc. (DARE)
Daré Bioscience, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Daré Bioscience, Inc. (DARE) is a Biotechnology company based in US with a market capitalization of $11.9M. Revenue grew 10429.4% year-over-year and free cash flow was negative at -$10.3B. This page tracks DARE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 21 employees · IPO Apr 10, 2014
Valuation
Valuation & price
$2.17as of May 17, 2026· -33.6% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
4.19
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$11.9M
Market cap
10429.4%
Revenue growth (YoY)
-137.6%
Gross margin
-$10.3B
Free cash flow (USD)
-$22.1M
Net debt
Net cash position
1215.6%
Share dilution
0/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2022 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 14, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 17, 2026Filing
Delisting Notice
- 8-K eventJul 13, 2026Filing
Corporate Presentation Released
- 8-K eventJun 22, 2026Filing
Corporate Presentation Released
- 8-K eventJun 12, 2026Filing
Stockholder Meeting Results
- 8-K eventMay 18, 2026Filing
Equity Offering Completed
- 8-K eventMay 14, 2026Filing
Earnings Release
- Quarterly reportMay 14, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
Equity Offering Completed
- 8-K eventApr 22, 2026Filing
Corporate Presentation Update
- 8-K eventApr 20, 2026Filing
Equity Offering Completed
Questions
Frequently asked questions
What is Daré Bioscience, Inc.'s market cap?
Daré Bioscience, Inc. (DARE) has a market capitalization of $11.9M.
What is DARE's P/E ratio?
A meaningful P/E ratio is not available for DARE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is DARE's price-to-book (P/B) ratio?
DARE trades at 4.19 times book value per share.
Are insiders buying DARE stock?
SEC Form 4 filings show no open-market insider buys at Daré Bioscience, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.